Olga Vedrova
AstraZeneca
5 Papers
1 Citations
Olga Vedrova is an academic researcher from AstraZeneca. The author has contributed to research in topics: Internal medicine & Population. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With?
T. V. Kekeeva,Yulia Andreeva,Alexander S Tanas,A.I. Kalinkin,S V Khokhlova,Alexandra Tyulyandina,Anatoly Y. Popov,M. Volkonsky,N. M. Chernorubashkina,Valeria Saevets,Vadim N. Dmitriev,V M Nechushkina,Olga Vedrova,Sergei Andreev,S. M. Kutsev,Vladimir V Strelnikov +15 more
TL;DR: In this article , the authors analyzed the influence of ethnic variations, tumor purity, and neoadjuvant chemotherapy (CT) on the determination of homologous recombination deficiency (HRD) scores as well as to evaluate feasibility of HRD testing with the Amoy HRD Focus Assay in routine clinical practice.
ADAM: A multicenter, non-interventional, prospective cohort study for determination of prevalence of homologous recombination repair genes mutations (HRRm) in metastatic castrate-resistant prostate cancer (mCRPC)—Interim analysis.
Boris Y. Alexeev,L. N. Lyubchenko,M. Gordiev,Maxim L. Filipenko,Yu. V. Anzhiganova,Alexander Bystrov,Alexander Orlov,Galina Gopp,Evgeny Kopyltsov,Alexander Lykov,Vagif A. Atduev,Galina Alekseeva,O.A. Mailyan,Vladislav L. Semenov,Olga Vedrova,Alexander G. Perevoschikov,Sergei Andreev,Logacheva Evgenia +17 more
TL;DR: In this paper , the authors conducted the first study to evaluate prevalence of HRRm in mCRPC patients in Russia, where they used three different techniques: GeneReader NGS System, KAPA HyperPlus and SeqCap EZ Choice (Roche).
2
BRCA-associated ovarian cancer in the russian patient population. Analysis of the non-interventional study Ovatar
T. Tikhomirova,A. Tyulyandina,Array A. Rumyantsev,Edgar Israelyan,T. V. Kekeeva,Olga Vedrova,M. L. Filipenko,L. N. Lyubchenko,I. A. Demidova,E. N. Imyanitov,Sergei Andreev,S V Khokhlova,Valeria Saevets,G. B. Statsenko,L. A. Kolomiets,S. A. Tkachenko,I. A. Koroleva,A. S. Lisyanskaya,O. Bakashvili,L. Krikunova,E. P. Solovieva,D. Ponomarenko,L Yu Vladimirova,Sergey E. Krasilnikov,V. B. Shirinkin,D. D. Sakaeva,E. A. Rumyantseva,S. A. Emeliyanov,Daniil Stroyakovskiy,E. G. Novikova,E. A. Ronina,V. I. Vladimirov,O. Y. Novikova,L. Zagumennova,V. V. Gorobtsova,E. V. Cherepanova,E. N. Pashkova,V. Moiseyenko,F. G. Ivanova,D. Udovitsa,Vera Karaseva,S. A. Tyulyandin +41 more
TL;DR: Due to the high frequency of germinal and somatic BRCA1 / 2 mutations in the Russian patients it is recommended to conduct the advanced testing methods not only in blood samples but also in tumor tissue.
Abstract 1241: Profile of BRCA1/BRCA2 mutations in Russian ovarian cancer population detected by NGS and MLPA analysis: Interim results of OVATAR study
Alexandra Tyulyandina,Vera Gorbunova,Svetlana Victorovna Khokhlova,Larisa Kolomiets,Maksim Filipenko,Evgeny N. Imyanitov,I. A. Demidova,Yuri Moliaka,Nadezhda V. Cherdyntseva,Dmitriy Vodolajskiy,Ludmila Lyubchenko,Sergei Tjulandin,Ilya Tsimafeyeu,Olga Vedrova,Vera Karaseva,Sergei Andreev,Tatiana Kekeeva +16 more
TL;DR: The overall rate of both somatic and germline BRCA variations in Russian OC population is in line with global data, with high percent of 8 frequent gBRCAm (49.3%).
Multicenter non-interventional study of prevalence of homologous recombination gene mutations and approaches to treatment of metastatic castration-resistant prostate cancer in Russia (ADAM)
B. Alekseev,Yu. V. Anzhiganova,A. V. Sultanbaev,Alexander Bystrov,Alexander Orlov,Galina Gopp,A. V. Kopyltsov,Alexander Lykov,V. A. Atduev,Galina Alekseeva,L. M. Rodygin,S. A. Varlamov,A. V. Shestakov,M. R. Maturov,M. F. Urmantsev,L. V. Lankina,E. Parsadanova,V. Y. Startsev,Olga Vedrova,Sergei Andreev,A. A. Perevoshchikov,O. A. Mailyan,A. S. Kalpinskiy +22 more
- 17 Aug 2024